The trial builds off the previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in patients ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

In a viewpoint paper recently published in the journal The Lancet Digital Health, a team led by Stanisa Raspopovic from ...

A scientific team looks at the progress and challenges in the research and development of brain implants. New achievements in the field of this technology are seen as a source of hope for many ...

Medidata has announced the extension of its partnership of 13 years with Tigermed to enhance clinical trial processes.

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Read about the UK nursing regulator's five “key lines of enquiry” for the next phase of its pre-registration practice ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical ...

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...